{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:35:17Z","timestamp":1793900117433,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.vaccine.2023.05.002","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T03:35:39Z","timestamp":1683516939000},"page":"4190-4198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults\u00a0\u226565 years old"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3007-6818","authenticated-orcid":false,"given":"David","family":"Fitz-Patrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Yacisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"McElwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3399-9979","authenticated-orcid":false,"given":"Todd","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung-Yang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-145X","authenticated-orcid":false,"given":"Daniel A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.05.002_b0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22310","article-title":"Risk factors for hospitalization, mechanical ventilation, or death among 10131 US veterans with SARS-CoV-2 infection","volume":"3","author":"Ioannou","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2023.05.002_b0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12877-021-02340-5","article-title":"Age differences in the association of comorbid burden with adverse outcomes in SARS-CoV-2","volume":"21","author":"O'Hare","year":"2021","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.vaccine.2023.05.002_b0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1469-0691.2012.03937.x","article-title":"Understanding the burden of pneumococcal disease in adults","volume":"18","author":"Blasi","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2023.05.002_b0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/1469-0691.12461","article-title":"Pneumococcal infection in adults: burden of disease","volume":"20","author":"Drijkoningen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2023.05.002_b0025","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1016\/j.vaccine.2020.06.082","article-title":"A global agenda for older adult immunization in the COVID-19 era: a roadmap for action","volume":"39","author":"Privor-Dumm","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.05.002_b0030","first-page":"129","article-title":"Pneumococcal vaccines WHO position paper\u20142012","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2023.05.002_b0035","first-page":"1","article-title":"The epidemiologic and biologic basis for classifying older age as a high-risk, immunocompromising condition for pneumococcal vaccine policy","author":"Grant","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.05.002_b0040","unstructured":"World Health Organization. WHO coronavirus disease (COVID-19) dashboard; 2022. https:\/\/covid19.who.int [accessed September 29, 2022]."},{"key":"10.1016\/j.vaccine.2023.05.002_b0045","doi-asserted-by":"crossref","unstructured":"GBD Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018;18:1191\u2013210. doi: 10.1016\/S1473-3099(18)30310-4.","DOI":"10.1016\/S1473-3099(18)30310-4"},{"key":"10.1016\/j.vaccine.2023.05.002_b0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmi.2020.07.041","article-title":"Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study","volume":"27","author":"Garcia-Vidal","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2023.05.002_b0055","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.medcli.2020.05.022","article-title":"Pneumococcal superinfection in COVID-19 patients: a series of 5 cases","volume":"155","author":"Cucchiari","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.vaccine.2023.05.002_b0060","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/14760584.2020.1825951","article-title":"Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations","volume":"19","author":"Sultana","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.05.002_b0065","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.05.002_b0070","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.05.002_b0075","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.05.002_b0080","unstructured":"Pfizer Inc. Highlights of prescribing information: Prevnar 20\u2122 (pneumococcal 20-valent conjugate vaccine). Philadelphia, PA: Pfizer Inc; 2021."},{"key":"10.1016\/j.vaccine.2023.05.002_b0085","unstructured":"Apexxnar (pneumococcal polysaccharide conjugate vaccine, 20-valent, adsorbed). Summary of Product Characteristics, Pfizer Europe MA EEIG Bruxelles, Belgium 2022."},{"key":"10.1016\/j.vaccine.2023.05.002_b0090","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/microorganisms9040738","article-title":"Serotype distribution of remaining pneumococcal meningitis in the mature pcv10\/13 period: findings from the PSERENADE project","volume":"9","author":"Garcia Quesada","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2023.05.002_b0095","unstructured":"Pfizer Inc. PREVNAR 20 prescribing information; 2021. https:\/\/www.fda.gov\/media\/149987\/download [accessed August 12, 2021]."},{"key":"10.1016\/j.vaccine.2023.05.002_b0100","unstructured":"World Health Organization. Good practice statement on the use of second booster doses for COVID-19 vaccines; 2021. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/361714\/WHO-2019-nCoV-Vaccines-SAGE-Boosters-2022.1-eng.pdf [accessed September 29, 2022]."},{"key":"10.1016\/j.vaccine.2023.05.002_b0105","unstructured":"Pfizer Inc. Highlights of prescribing information: Comirnaty\u00ae (COVID-19 Vaccine. New York, NY: Pfizer Inc; 2021."},{"key":"10.1016\/j.vaccine.2023.05.002_b0110","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:109\u201317. doi: 10.15585\/mmwr.mm7104a1.","DOI":"10.15585\/mmwr.mm7104a1"},{"key":"10.1016\/j.vaccine.2023.05.002_b0115","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1093\/cid\/ciaa1728","article-title":"Impact of the coronavirus disease 2019 (COVID-19) pandemic on invasive pneumococcal disease and risk of pneumococcal coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): prospective national cohort study, England","volume":"72","author":"Amin-Chowdhury","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.05.002_b0120","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1016\/j.vaccine.2011.05.031","article-title":"A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged \u2265 65 years","volume":"29","author":"Schwarz","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.05.002_b0125","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1128\/CVI.00176-12","article-title":"Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults","volume":"19","author":"Frenck","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2023.05.002_b0130","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/21645515.2018.1533777","article-title":"Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial","volume":"15","author":"Thompson","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.05.002_b0135","article-title":"Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: a phase 3 randomized trial","author":"Cannon","year":"2022","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23005200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23005200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:27:42Z","timestamp":1759404462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23005200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":27,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0264410X23005200"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.002","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults\u00a0\u226565 years old","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}